Journal: Materials Today Bio

Article Title: Polymeric PD1/PDL1 bispecific antibody enhances immune checkpoint blockade therapy

doi: 10.1016/j.mtbio.2024.101239

Figure Lengend Snippet: BsAb αPD1+αPDL1 simultaneously binds PD1 on the tumor cell and PDL1 on the CD8 + T cell, engaging both cell types together while reinvigorating the CD8 + T cells, further contributing to tumor cell death.

Article Snippet: Anti-mouse PD1 antibody (αPD1, Rat IgG1, κ; Catalog: BE0146), anti-mouse PDL1 antibody (αPDL1, Rat IgG2b, κ; Catalog: BE0101) were procured from Bio X Cell (West Lebanon, NH, USA).

Techniques:

Journal: Materials Today Bio

Article Title: Polymeric PD1/PDL1 bispecific antibody enhances immune checkpoint blockade therapy

doi: 10.1016/j.mtbio.2024.101239

Figure Lengend Snippet: Synthesis and characterization of BsAb αPD1+αPDL1 . (A) Schematic representation and preparation of BsAb αPD1+αPDL1 . (B) Transmission electron microscopy (TEM) images of BsAb αPD1+αPDL1 (Scale bar: 1 μm). (C) Molecular weight of αPD1, αPDL1 and BsAb αPD1+αPDL1 , as measured by asymmetric flow field-flow fractionation coupled with multiangle laser light scattering. (D) Particle size of PGLU-Fc-III-4C and BsAb αPD1+αPDL1 , as detected by DLS. Average diameters for each sample are shown. (E) The molecular weights of PGLU, PGLU-Fc-III-4C, BsAb αPD1+αPDL1 were measured with Gel Permeation Chromatography (GPC). (F) Flow cytometric analysis detecting FITC labeled anti-PD1 and PE-Cy7 labeled anti-PDL1 antibodies conjugated into a BsAb αPD1+αPDL1 .

Article Snippet: Anti-mouse PD1 antibody (αPD1, Rat IgG1, κ; Catalog: BE0146), anti-mouse PDL1 antibody (αPDL1, Rat IgG2b, κ; Catalog: BE0101) were procured from Bio X Cell (West Lebanon, NH, USA).

Techniques: Transmission Assay, Electron Microscopy, Molecular Weight, Field Flow Fractionation, GPC Assay, Labeling

Journal: Materials Today Bio

Article Title: Polymeric PD1/PDL1 bispecific antibody enhances immune checkpoint blockade therapy

doi: 10.1016/j.mtbio.2024.101239

Figure Lengend Snippet: In vitro stability testing, tumor inhibition and CD8 + T cell activation activity of BsAb αPD1+αPDL1 . (A) Schematic representation of the experimental of stability testing. (B) Flow cytometry analysis detecting the stimulative stability of PGLU-Fc-III-4C-hIgG-PE-Cy7 in human blood in 72 h, in which the hIgG was 9.5 g/L. PGLU-Fc-III-4C without hIgG-PE-Cy7 was used as a control for gating. (C) Schematic representation of the experimental process assessing in vitro activity of BsAb αPD1+αPDL1 in a co-culture of MC38 cells and CD8 + T cells. (D–F) IFN-γ, perforin, and granzyme B ELISA results from supernatants of co-cultured MC38 cells and CD8 + T cells at 24 h after treatment. (G) CCK-8 assay detecting different drugs induced anti-tumor effect of CD8 + T cells.

Article Snippet: Anti-mouse PD1 antibody (αPD1, Rat IgG1, κ; Catalog: BE0146), anti-mouse PDL1 antibody (αPDL1, Rat IgG2b, κ; Catalog: BE0101) were procured from Bio X Cell (West Lebanon, NH, USA).

Techniques: In Vitro, Inhibition, Activation Assay, Activity Assay, Flow Cytometry, Control, Co-Culture Assay, Enzyme-linked Immunosorbent Assay, Cell Culture, CCK-8 Assay

Journal: Materials Today Bio

Article Title: Polymeric PD1/PDL1 bispecific antibody enhances immune checkpoint blockade therapy

doi: 10.1016/j.mtbio.2024.101239

Figure Lengend Snippet: (A) Optical microscope photographs of the cocultured MC38 and CD8 + T cells at 6 h after treatment with PBS, NP αPD1 +NP αPD1 and BsAb αPD1+αPDL1. In vivo biodistribution of Cy5-labeled NP αPD1 +NP αPD1 and BsAb αPD1+αPDL1. (B) In vivo fluorescent imaging of drug distribution in mice at 4 h and 24 h post-injection and quantitative analysis of the fluorescence in the tumor (n = 3 mice/group).

Article Snippet: Anti-mouse PD1 antibody (αPD1, Rat IgG1, κ; Catalog: BE0146), anti-mouse PDL1 antibody (αPDL1, Rat IgG2b, κ; Catalog: BE0101) were procured from Bio X Cell (West Lebanon, NH, USA).

Techniques: Microscopy, In Vivo, Labeling, Imaging, Injection, Fluorescence

Journal: Materials Today Bio

Article Title: Polymeric PD1/PDL1 bispecific antibody enhances immune checkpoint blockade therapy

doi: 10.1016/j.mtbio.2024.101239

Figure Lengend Snippet: H&E staining of tumors (Scale bar: 400 μm) and representative immunofluorescence images of tumors (Scale bar: 500 μm) after BsAb αPD1+αPDL1 treatment.

Article Snippet: Anti-mouse PD1 antibody (αPD1, Rat IgG1, κ; Catalog: BE0146), anti-mouse PDL1 antibody (αPDL1, Rat IgG2b, κ; Catalog: BE0101) were procured from Bio X Cell (West Lebanon, NH, USA).

Techniques: Staining, Immunofluorescence

Journal: Journal of Nanobiotechnology

Article Title: A radioenhancing nanoparticle mediated immunoradiation improves survival and generates long-term antitumor immune memory in an anti-PD1-resistant murine lung cancer model

doi: 10.1186/s12951-021-01163-1

Figure Lengend Snippet: Treatment outcomes after therapy with NBTXR3, high- and low-dose radiotherapy, and immunotherapy. A Treatment schema for NBTXR3 given with high-dose and low-dose radiotherapy. Mice were subcutaneously inoculated with 5 × 10 4 344SQR cells in the right legs on day 0 (to establish primary tumors) and in the left legs on day 3 (to establish secondary tumors). NBTXR3 was delivered to the primary tumor by intratumoral injection on day 6. Primary tumors were treated with three 12-Gy fractions on day 7, 8, and 9 (HDXRT). Secondary tumors were irradiated with two 1-Gy fractions on day 12 and 13 (LDXRT). Anti-PD1 (200 μg) and anti-CTLA4 (100 μg) were given by intraperitoneal injection on days 4, 7, 10, and 13, and anti-PD1 treatment was continued once a week from day 20 until day 62. B Changes in primary tumor volumes over time. C Changes in secondary tumor volumes over time. Data are shown as means for each treatment group (n = 7 or 8), with bars indicating standard error of the mean. D Survival rates and median survival times for each treatment group. E Number of spontaneous lung metastases on day 16 in each treatment group. All of the mice were injected with both anti-PD1 and anti-CTLA4, and all mice were euthanized when the any tumor exceeded 14 mm in diameter. F Individual primary tumor volumes for each treatment group. G Individual secondary tumor volumes for each treatment group. Data are expressed as means ± standard error of the mean (SEM). P < 0.05 was considered statistically significant. * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001, NS not significant. HDXRT high-dose radiotherapy; LDXRT low-dose radiotherapy; ICIs immune checkpoint inhibitors

Article Snippet: The mouse anti-PD1 antibody (αPD1) (mPD1-4H2-mg1-D265aA) was kindly provided by Bristol-Myers Squibb.

Techniques: Injection, Irradiation

Journal: Biomarker Research

Article Title: Targeting TIGIT for cancer immunotherapy: recent advances and future directions

doi: 10.1186/s40364-023-00543-z

Figure Lengend Snippet: Selected Preclinical studies of anti-TIGIT agents in solid and hematological tumors

Article Snippet: , VV- scFv- TIGIT b [ ] , 200 μg (anti-PD-1) i.p. every 2 days for 6–7 doses 200 μg (anti-LAG-3) i.p. every 4 days for 3 doses , CT26, MC38,4 T1, H22 bearing BALB/c or C57BL/6 mouse model , The intratumoral injection of VV-scFv-TIGIT elicited anti-tumor function, prolonged survival, increased T cells infiltration and activation of CD8 + T cells. Combination of anti-PD-1 or anti-LAG-3 enhanced the anti-tumor efficacy. , Anti-PD-1 (αPD1, Clone RMP1–14, Cat# BE0146, BioXCell) Anti-LAG3 (αLAG- 3, Clone C9B7W, Cat# BE0174, BioXCell) , Colorectal Carcinoma Breast Cancer Hepatocellular Carcinoma.

Techniques: Knock-In, Cell Function Assay, Injection, Activation Assay, Amplification, Control, Incubation, Lysis